The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability
Open accessAbstract
Mutations in the phosphatase and tensin homolog (PTEN) gene leading to PTEN protein deletion and subsequent activation of the PI3K/Akt signaling pathway are common in cancer. Here we show that PTEN inactivation in human T cell acute lymphoblastic leukemia (T-ALL) cells is not always synonymous with PTEN gene lesions and diminished protein expression. Samples taken from patients with T-ALL at the time of diagnosis very frequently showed constitutive hyperactivation of the PI3K/Akt pathway. In contrast to immortalized cell lines, most primary T-ALL cells did not harbor PTEN gene alterations, displayed normal PTEN mRNA levels, and expressed higher PTEN protein levels than normal T cell precursors. However, PTEN overexpression was associated with decreased PTEN lipid phosphatase activity, resulting from casein kinase 2 (CK2) overexpression and hyperactivation. In addition, T-ALL cells had constitutively high levels of ROS, which can also downmodulate PTEN activity. Accordingly, both CK2 inhibitors and ROS scavengers restored PTEN activity and impaired PI3K/Akt signaling in T-ALL cells. Strikingly, inhibition of PI3K and/or CK2 promoted T-ALL cell death without affecting normal T cell precursors. Overall, our data indicate that T-ALL cells inactivate PTEN mostly in a nondeletional, posttranslational manner. Pharmacological manipulation of these mechanisms may open new avenues for T-ALL treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Román‐Gómez, J., Jiménez‐Velasco, A., Agirre, X., Prósper, F., Heiniger, A., & Torres, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.4944 · Cited by 128
RetractedThe phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Production of large amounts of hydrogen peroxide by human tumor cells.
Szatrowski, T. P., & Nathan, C. (1991) · PubMed · Cited by 3,007
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,715
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Mitogenic Signaling Mediated by Oxidants in Ras-Transformed Fibroblasts
Irani, K., Xia, Y., Zweier, J. L., Sollott, S. J., Der, C. J., Fearon, E. R., Sundaresan, M., Finkel, T., & Goldschmidt-Clermont, P. J. (1997) · Science · doi:10.1126/science.275.5306.1649 · Cited by 1,588
Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress
Kops, G. J. P. L., Dansen, T. B., Polderman, P. E., Saarloos, I., Wirtz, K. W. A., Coffer, P. J., Huang, T.-T., Bos, J. L., Medema, R. H., & Burgering, B. M. T. (2002) · Nature · doi:10.1038/nature01036 · Cited by 1,580 · cited 1×
“The Akt substrates FOXO transcription factors were shown to downregulate ROS levels (54, 55), and FOXO1/3/4 full knockout mice develop thymic lymphomas (56).”
BackgroundFoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress
Tothova, Z., Kollipara, R., Huntly, B. J., Lee, B. H., Castrillon, D. H., Cullen, D. E., McDowell, E. P., Lazo-Kallanian, S., Williams, I. R., Sears, C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.003 · Cited by 1,562 · cited 1×
“The Akt substrates FOXO transcription factors were shown to downregulate ROS levels (54, 55), and FOXO1/3/4 full knockout mice develop thymic lymphomas (56).”
BackgroundPten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516
Cell transformation by the superoxide-generating oxidase Mox1
Suh, Y.-A., Arnold, R. S., Lassegue, B., Shi, J., Xu, X., Sorescu, D., Chung, A. B., Griendling, K. K., & Lambeth, J. D. (1999) · Nature · doi:10.1038/43459 · Cited by 1,480
Cited by
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth
Zhang, L., Zhang, S., Yao, J., Lowery, F. J., Zhang, Q., Huang, W.-C., Li, P., Li, M., Wang, X., Zhang, C., et al. (2015) · Nature · doi:10.1038/nature15376 · Cited by 1,175
The functions and regulation of the PTEN tumour suppressor: new modes and prospects
Lee, Y.-R., Chen, M., & Pandolfi, P. P. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0015-0 · Cited by 917
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3037 · Cited by 794
Zhou, D., Huang, C., Lin, Z., Zhan, S., Kong, L., Fang, C., & Li, J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2013.11.004 · Cited by 778
Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 642
Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C. R., Long, J., Laidler, P., Mijatovic, S., Maksimovic-Ivanic, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 553
Nogueira, V., & Hay, N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1424 · Cited by 514
PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control
Georgescu, M.-M. (2010) · Genes & Cancer · doi:10.1177/1947601911407325 · Cited by 482
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia
Gutierrez, A., Sanda, T., Grebliunaite, R., Carracedo, A., Salmena, L., Ahn, Y., Dahlberg, S., Neuberg, D., Moreau, L. A., Winter, S. S., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206722 · Cited by 437
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia
Zenatti, P. P., Ribeiro, D., Li, W., Zuurbier, L., Silva, M. C., Paganin, M., Tritapoe, J., Hixon, J. A., Silveira, A. B., Cardoso, B. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.924 · Cited by 416
Self-citationMechanisms of PTEN loss in cancer: It’s all about diversity
Álvarez-Garcia, V., Tawil, Y., Wise, H. M., & Leslie, N. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.001 · Cited by 401
Self-citationCancer prevention and therapy through the modulation of the tumor microenvironment
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.007 · Cited by 372
The genetics and molecular biology of T-ALL
Girardi, T., Vicente, C., Cools, J., & De Keersmaecker, K. (2017) · Blood · doi:10.1182/blood-2016-10-706465 · Cited by 355
Addiction to protein kinase CK2: A common denominator of diverse cancer cells?
Ruzzene, M., & Pinna, L. A. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.07.018 · Cited by 352
Portrait of the PI3K/AKT pathway in colorectal cancer
Danielsen, S. A., Eide, P. W., Nesbakken, A., Guren, T., Leithe, E., & Lothe, R. A. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.09.008 · Cited by 321
PTEN function: the long and the short of it
Hopkins, B. D., Hodakoski, C., Barrows, D., Mense, S. M., & Parsons, R. E. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.006 · Cited by 309
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.652 · Cited by 306
Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human Diseases
Uversky, V. N., Davé, V., Iakoucheva, L. M., Malaney, P., Metallo, S. J., Pathak, R. R., & Joerger, A. C. (2014) · Chemical Reviews · doi:10.1021/cr400713r · Cited by 288
Regulation of protein tyrosine phosphatases by reversible oxidation
Östman, A., Frijhoff, J., Sandin, Å., & Böhmer, F.-D. (2011) · The Journal of Biochemistry · doi:10.1093/jb/mvr104 · Cited by 288
Ma, X.-H., Piao, S., Wang, D., Mcafee, Q. W., Nathanson, K. L., Lum, J. J., Li, L. Z., & Amaravadi, R. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2372 · Cited by 234
Canté-Barrett, K., Spijkers-Hagelstein, J. A. P., Buijs-Gladdines, J. G. C. A. M., Uitdehaag, J. C. M., Smits, W. K., van der Zwet, J., Buijsman, R. C., Zaman, G. J. R., Pieters, R., & Meijerink, J. P. P. (2016) · Leukemia · doi:10.1038/leu.2016.83 · Cited by 94
Acylglycerol Kinase Maintains Metabolic State and Immune Responses of CD8+ T Cells
Hu, Z., Qu, G., Yu, X., Jiang, H., Teng, X.-L., Ding, L., Hu, Q., Guo, X., Zhou, Y., Wang, F., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.05.016 · Cited by 87
Lo, T. C. T., Barnhill, L. M., Kim, Y., Nakae, E. A., Yu, A. L., & Diccianni, M. B. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.04.032 · Cited by 59
“Recently, phosphorylation of PTEN has been reported as an alternative mechanism of protein inactivation and Akt activation [3].”
Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment
Cramer, S. D., Aplan, P. D., & Durum, S. K. (2016) · Blood · doi:10.1182/blood-2016-03-679209 · Cited by 43
“PTEN activity can also be decreased by posttranslational effects such as casein kinase 2 (CK2) overexpression, high levels of reactive oxygen species (ROS), or miRNAs.(32,33)”
BackgroundResultPTEN in Regulating Hematopoiesis and Leukemogenesis
Wu, Y., Zhu, H., & Wu, H. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036244 · Cited by 22
Metadata
- Authors
- Silva, A., Yunes, J. A., Cardoso, B. A., Martins, L. R., Jotta, P. Y., Abecasis, M., Nowill, A. E., Leslie, N. R., Cardoso, A. A., & Barata, J. T.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-11-03
- Volume
- 118
- Issue
- 11
- Pages
- 3762-3774
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2140154966
- Cited by
- 443
- References
- 64
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.